Newsletter | November 19, 2026

11.19.26 -- The Hidden Challenge Between Molecule And Medicine

SPONSOR

Mastering Aseptic Fill-Finish | Dec. 1, 2026, 11:00 AM ET

This session explores aseptic fill-finish manufacturing, focusing on contamination control, regulatory compliance, and sterile processing best practices. Industry experts will discuss the value of early sponsor-CDMO collaboration, effective program planning, platform technologies, and quality-focused manufacturing strategies. Attendees will gain insights into maintaining product integrity, supporting successful scale-up, and ensuring commercial readiness through every stage of fill-finish operations.

INDUSTRY INSIGHTS

Sample-Attribute-Based Selection Strategies For AAV %Full Determination

AAV %Full analysis must distinguish full, empty, and partial capsids, with complementary methods selected according to sample characteristics, analytical needs, development stage, and context.

Exploring The Genetic Tools Enabling Protein Expression In Fruit Flies

Fruit fly genetics enables precise, scalable protein expression through stable integration, targeted control, inducible regulation, and heritable systems.

The Benefits Of Customs Warehouse For Pharmaceutical Supply Chains

Learn how leveraging a customs warehouse can streamline your supply chain, reduce VAT costs, and enhance global compliance and efficiency.

FEATURED EDITORIAL

The Hidden Challenge Between Molecule And Medicine

Over two days in Boston, biopharma leaders at CDMO Live Americas confronted a blunt truth: the outsourcing sector doesn't lack ambition or stainless steel, it has a widening gap between partnership intent and shop-floor delivery.

CDMO Live Europe 2026: Partnerships For An Uncertain World

112 pages of executive insight from CDMO Live Europe 2026: tariffs, geopolitics, supply resilience, AI in manufacturing, and why strategic partnerships remain aspirational for most.

INDUSTRY INSIGHTS CONTINUED

Discover Accelerated Approaches For Successful Commercial Filing

Early risk assessment, leaner scale-down model qualification, and tighter process characterization scope offer the clearest time savings in microbial filings, each with scientific trade-offs worth weighing.

A Smooth Transition To USP <382> With Established Expertise

A new regulatory chapter requires holistic, real‑world testing of injectable systems, mandating full‑system validation with actual drug products and prioritizing patient‑centric performance and safety.

Flow Chemistry For Contemporary Isotope Labeling

View how late‑stage exchange and flow‑based methods enable efficient access to labeled molecules for pharmaceuticals, mechanistic studies, and analytical applications.

Avoid CapEX With Improved Operational Efficiencies

Avoid massive capital expenditures by optimizing supply chain logistics. Assimilate how off-site material sampling and just-in-time delivery reduce lead times from eight weeks to a single day.

Innovations In Perfusion Bioprocessing

Gain valuable insight into the optimization and scalability of perfusion media and processes, driving progress in biotechnological processes for monoclonal antibody production.

Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs

Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

What Downstream Deviations Reveal About Upstream Process Maturity

Fill finish deviations can reveal upstream process issues early. Identifying these signals helps reduce variability, improve process control, and strengthen sterile injectable manufacturing.

Sterile Fill Finish Manufacturing At Scale

Upstream decisions directly dictate late-stage sterile fill-finish success. Read how aligning drug substance synthesis, formulation design, and aseptic filling early mitigates operational risks.

ADCs Vs. AOCs: Key Differences In Bioconjugate Engineering

Uncover how payload size, charge density, and linker dynamics shape clearance, loading ratios, and intracellular delivery in next-generation oligonucleotide bioconjugates.

Why Sterile Manufacturing Matters For ADC And CDMO Success

Rising complexity in ADCs and biologics makes sterile manufacturing more critical than ever. Explore approaches to outsourcing, lyophilization, and quality management that support success.

Where Formulation Expertise Connects

As pipelines grow more complex and timelines become more ambitious, companies increasingly rely on strong external partners to advance their drug products efficiently and with reduced risk. 

SOLUTIONS

Accelerating ADC Development From Concept To Commercialization

Step Inside Our Sterile Injectable Campus

ADC Outsourcing Is Now A Global Strategy

The Large Molecule Partner Designed For Speed And Quality

Path To IND For Biologics Delivers Phase 1 Material In As Few As 9 Months*

Biosafety Testing

Guaranteed Tech Transfer And Process Development – Or Your Money Back

OUTSOURCED PHARMA CAPABILITIES UPDATE

Find Your New CDMO At Outsourced Pharma Capabilities Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: